Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial

By Adria Calatayud


Sanofi said its rilzabrutinib drug candidate met a primary goal of a late-stage clinical trial in immune thrombocytopenia, a blood disorder, paving the way for regulatory...

Related Keywords

France ,French ,Adria Calatayud ,European Union ,Dow Jones ,Markets ,